Communicating effectively about appropriate options and eliciting patient input for overactive bladder (OAB) can improve outcomes.
Regardless of delivery type, obesity ups the risk of more severe urinary symptoms, study shows.
In a study, severe nocturia predicted increased mortality risk.
Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.
Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.
Improvements in efficacy and quality of life last at least six months, study finds.
Depression risk greater for men with nocturia than for women with nocturia.
Two studies show significant reduction in number of nocturnal voids for women.
In most responders, overactive bladder symptom improvement sustained to three years.
Products advertised through fax; not FDA approved.
Oxytrol is intended for use by those 18 and older.
Increasing the daily dose from 5 to 10 mg resulted in reductions in mean total urgency score and mean micturition frequency.
The FDA has approved onabotulinumtoxinA (Botox) as a treatment for overactive bladder (OAB) in adults who are inadequately managed with anticholinergic medications.
Patients with type 2 diabetes are twice as likely as nondiabetics to suffer from the condition.
Mirabegron is the first oral OAB drug with a distinct mechanism of action to be approved in three decades.
Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.